Logo image of FATE

FATE THERAPEUTICS INC (FATE) Stock Fundamental Analysis

NASDAQ:FATE - Nasdaq - US31189P1021 - Common Stock - Currency: USD

1.42  -0.12 (-8.09%)

After market: 1.4199 0 (-0.01%)

Fundamental Rating

3

Overall FATE gets a fundamental rating of 3 out of 10. We evaluated FATE against 571 industry peers in the Biotechnology industry. While FATE has a great health rating, there are worries on its profitability. FATE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FATE had negative earnings in the past year.
In the past year FATE has reported a negative cash flow from operations.
In the past 5 years FATE always reported negative net income.
In the past 5 years FATE always reported negative operating cash flow.
FATE Yearly Net Income VS EBIT VS OCF VS FCFFATE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100M -200M -300M

1.2 Ratios

FATE has a Return On Assets of -36.01%. This is in the better half of the industry: FATE outperforms 60.57% of its industry peers.
The Return On Equity of FATE (-49.19%) is better than 66.07% of its industry peers.
Industry RankSector Rank
ROA -36.01%
ROE -49.19%
ROIC N/A
ROA(3y)-31.58%
ROA(5y)-31.01%
ROE(3y)-44.38%
ROE(5y)-43.67%
ROIC(3y)N/A
ROIC(5y)N/A
FATE Yearly ROA, ROE, ROICFATE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

FATE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FATE Yearly Profit, Operating, Gross MarginsFATE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K

More info and screens

7

2. Health

2.1 Basic Checks

FATE does not have a ROIC to compare to the WACC, probably because it is not profitable.
FATE has more shares outstanding than it did 1 year ago.
FATE has more shares outstanding than it did 5 years ago.
There is no outstanding debt for FATE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
FATE Yearly Shares OutstandingFATE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M
FATE Yearly Total Debt VS Total AssetsFATE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M 800M

2.2 Solvency

FATE has an Altman-Z score of -3.70. This is a bad value and indicates that FATE is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -3.70, FATE perfoms like the industry average, outperforming 43.69% of the companies in the same industry.
FATE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.7
ROIC/WACCN/A
WACC9.44%
FATE Yearly LT Debt VS Equity VS FCFFATE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

FATE has a Current Ratio of 8.29. This indicates that FATE is financially healthy and has no problem in meeting its short term obligations.
With a decent Current ratio value of 8.29, FATE is doing good in the industry, outperforming 72.82% of the companies in the same industry.
A Quick Ratio of 8.29 indicates that FATE has no problem at all paying its short term obligations.
FATE has a Quick ratio of 8.29. This is in the better half of the industry: FATE outperforms 73.00% of its industry peers.
Industry RankSector Rank
Current Ratio 8.29
Quick Ratio 8.29
FATE Yearly Current Assets VS Current LiabilitesFATE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

FATE shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.78%.
FATE shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.34%.
FATE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 68.05% yearly.
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
Revenue 1Y (TTM)-87.34%
Revenue growth 3Y26.44%
Revenue growth 5Y68.05%
Sales Q2Q%58.13%

3.2 Future

Based on estimates for the next years, FATE will show a quite strong growth in Earnings Per Share. The EPS will grow by 8.48% on average per year.
FATE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -12.71% yearly.
EPS Next Y-1.31%
EPS Next 2Y-2.49%
EPS Next 3Y2%
EPS Next 5Y8.48%
Revenue Next Year-78.85%
Revenue Next 2Y-75.07%
Revenue Next 3Y-62.54%
Revenue Next 5Y-12.71%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
FATE Yearly Revenue VS EstimatesFATE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M
FATE Yearly EPS VS EstimatesFATE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

FATE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year FATE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FATE Price Earnings VS Forward Price EarningsFATE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FATE Per share dataFATE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.49%
EPS Next 3Y2%

More info and screens

0

5. Dividend

5.1 Amount

FATE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FATE THERAPEUTICS INC

NASDAQ:FATE (2/21/2025, 8:16:50 PM)

After market: 1.4199 0 (-0.01%)

1.42

-0.12 (-8.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners88.96%
Inst Owner Change-97.73%
Ins Owners2%
Ins Owner Change1.77%
Market Cap161.72M
Analysts73.33
Price Target6.46 (354.93%)
Short Float %11.77%
Short Ratio5.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)20.6%
Min EPS beat(2)9.28%
Max EPS beat(2)31.92%
EPS beat(4)4
Avg EPS beat(4)15.63%
Min EPS beat(4)5.72%
Max EPS beat(4)31.92%
EPS beat(8)8
Avg EPS beat(8)24.68%
EPS beat(12)11
Avg EPS beat(12)18.03%
EPS beat(16)12
Avg EPS beat(16)10.74%
Revenue beat(2)2
Avg Revenue beat(2)249.31%
Min Revenue beat(2)127.37%
Max Revenue beat(2)371.26%
Revenue beat(4)4
Avg Revenue beat(4)142.75%
Min Revenue beat(4)3.08%
Max Revenue beat(4)371.26%
Revenue beat(8)7
Avg Revenue beat(8)102.95%
Revenue beat(12)10
Avg Revenue beat(12)83.9%
Revenue beat(16)14
Avg Revenue beat(16)93.55%
PT rev (1m)0.41%
PT rev (3m)0.41%
EPS NQ rev (1m)-0.54%
EPS NQ rev (3m)-0.54%
EPS NY rev (1m)3.5%
EPS NY rev (3m)3.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)18.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.03
P/FCF N/A
P/OCF N/A
P/B 0.45
P/tB 0.45
EV/EBITDA N/A
EPS(TTM)-1.65
EYN/A
EPS(NY)-1.72
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)-1.16
OCFYN/A
SpS0.12
BVpS3.18
TBVpS3.18
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.01%
ROE -49.19%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-31.58%
ROA(5y)-31.01%
ROE(3y)-44.38%
ROE(5y)-43.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.28%
Cap/Sales 6.06%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.29
Quick Ratio 8.29
Altman-Z -3.7
F-Score2
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)386.28%
Cap/Depr(5y)331.25%
Cap/Sales(3y)45.8%
Cap/Sales(5y)44.47%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%13.04%
EPS Next Y-1.31%
EPS Next 2Y-2.49%
EPS Next 3Y2%
EPS Next 5Y8.48%
Revenue 1Y (TTM)-87.34%
Revenue growth 3Y26.44%
Revenue growth 5Y68.05%
Sales Q2Q%58.13%
Revenue Next Year-78.85%
Revenue Next 2Y-75.07%
Revenue Next 3Y-62.54%
Revenue Next 5Y-12.71%
EBIT growth 1Y4.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.93%
EBIT Next 3Y-3.99%
EBIT Next 5YN/A
FCF growth 1Y54.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y45.82%
OCF growth 3YN/A
OCF growth 5YN/A